Successful treatment of Epstein-Barr virus encephalitis in the setting of HIV-associated neurocognitive disorder: a diagnostic and therapeutic challenge

Grants

Funding Acknowledgements

JFH has served on advisory boards for Gilead Sciences, ViiV Healthcare, Janssen Cilag and Merck, Sharp & Dohme. Her institution has received research support from Merck, Sharp & Dohme and Gilead Sciences, and honoraria for speaking or chairing engagements from Gilead Sciences and Janssen Cilag. All other authors declare no competing interests.